Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cannabidiol,Aspartame
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : JW-100 (cannabidiol), met its primary endpoint in a recently completed Phase 1-equivalent international study in which Jupiter’s topical formulation cleared or reduced eczema following two weeks of use.
Brand Name : JW-100
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 11, 2021
Lead Product(s) : Cannabidiol,Aspartame
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cannabidiol,Aspartame
Therapeutic Area : Dermatology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Jupiter Wellness Applies for IND Number from the US Food and Drug Administration
Details : Jupiter Wellness previously reported that in a double-blinded, placebo controlled clinical trial of 55 patients using JW-100 was shown to significantly reduce ISGA scores in 50% of adult patients suffering from eczema after two weeks of use.
Brand Name : JW-100
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 16, 2021
Lead Product(s) : Cannabidiol,Aspartame
Therapeutic Area : Dermatology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cannabidiol,Aspartame
Therapeutic Area : Dermatology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Jupiter Wellness Advances Clinical Pipeline of CBD-Based Topical Treatments
Details : Jupiter Wellness commenced patient enrollment for skin cancer. Jupiter's JW-200 is designed to provide action and relief in the treatment of eczema, Actinic Keratosis, the most common precancer that forms on skin as a result of exposure to ultraviolet (...
Brand Name : JW-100
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 29, 2021
Lead Product(s) : Cannabidiol,Aspartame
Therapeutic Area : Dermatology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cannabidiol,Aspartame
Therapeutic Area : Dermatology
Study Phase : Approved
Sponsor : CURE Pharmaceutical
Deal Size : $44.0 million
Deal Type : Acquisition
CURE Pharmaceutical to Acquire Sera Labs in a $20 Million Transaction
Details : Acquisition of Sera Labs will add to CURE a growing brand portfolio and monetization platform that fits remarkably well with CURE’s development capabilities, products, and existing market verticals.
Brand Name : Seratopical
Molecule Type : Small molecule
Upfront Cash : $20.0 million
July 28, 2020
Lead Product(s) : Cannabidiol,Aspartame
Therapeutic Area : Dermatology
Highest Development Status : Approved
Sponsor : CURE Pharmaceutical
Deal Size : $44.0 million
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?